2010 Annual Scientific Meeting and Exposition 2010 Annual ...

Monday Morning Afternoon MAY 21 3PostersPO-237: 3PO-238: 3PO-239: 3PO-240: 3PO-241: 3Effects of an Amlodipine- and OlmesartanMedoxomil-Based Titration Regimen on 24-HourBP Profiles in Patients with Hypertension and Type2 DiabetesVenkata S. Ram, 1 Richard A. Sachson, 2 Thomas W.Littlejohn III, 3 Ali Shojaee, 4 Kathy A. Stoakes, 4 Joel M.Neutel. 5 1 University of Texas Southwestern MedicalCenter, US; 2 Endocrine Associates of Dallas, US;3 Piedmont Medical Research Associates, US; 4 DaiichiSankyo, Inc., US and 5 Orange County Research Center,US.New Angiotensin II Receptor Blocker AzilsartanMedoxomil Coadministered with ChlorthalidoneProvides Potent Blood Pressure Reduction in Stage 2HypertensionD. Sica†, 1 G. L. Bakris, 2 W. B. White, 3 M. A. Weber, 4 A.Perez, 5 C. Cao, 5 S. Kupfer. 5 1 Virginia CommonwealthUniversity Health System, Richmond, VA, US;2 University of Chicago, Pritzker School of Medicine,Chicago, IL, US; 3 University of Connecticut Schoolof Medicine, Farmington, CT, US; 4 SUNY DownstateCollege of Medicine, New York, IL, US and 5 TakedaGlobal Research & Development, Deerfield, IL, US.A Phase III Trial of Baroreflex Activation Therapyfor Resistant Hypertension: Trial Design andBaseline Characteristics in the Rheos Pivotal TrialDomenic A. Sica†, 1 George Bakris, 2 JohnBisognano, 3 Mitra Nadim, 4 Luis Sanchez. 5 1 VirginiaCommonwealth University Health System, Richmond,VA, US; 2 University of Chicago, US; 3 University ofRochester Medical Center, US; 4 University of SouthernCalifornia, US and 5 Washington University School ofMedicine, US.Morbidity and Mortality on Combination vsMonotherapy in the Systolic Hypertension in EuropeTrialLutgarde Thijs, 1 Tom Richart, 1,2 Peter W. de Leeuw, 2Tatiana Kuznetsova, 1 Tomasz Grodzicki, 3 KalinaKawecka-Jaszcz, 3 Eoin O’Brien, 4 Josep Redón, 5 WillemH. Birkenhäger, 6 Robert Fagard, 1 Jan A. Staessen†. 1,21 University of Leuven, BE; 2 Maastricht University,NL; 3 Jagiellonian University, PL; 4 University CollegeDublin, IE; 5 University of Valencia, ES and 6 ErasmusUniversity, NL.Antihypertensive Efficacy of the New AngiotensinReceptor Blocker Azilsartan Medoxomil inCombination with AmlodipineM. A. Weber†, 1 W. B. White, 2 D. Sica, 3 G. L. Bakris, 4A. Perez, 5 C. Cao, 5 S. Kupfer. 5 1 SUNY DownstateCollege of Medicine, New York, NY, US; 2 University ofConnecticut School of Medicine, Farmington, CT, US;3 Virginia Commonwealth University Health System,Richmond, VA, US; 4 University of Chicago, PritzkerSchool of Medicine, Chicago, IL, US and 5 TakedaGlobal Research & Development, Deerfield, IL, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track145